trending Market Intelligence /marketintelligence/en/news-insights/trending/q-zskt_2jxnmxuhv2gaapq2 content esgSubNav
In This List

Novo Nordisk seeks US, EU approval for hemophilia A treatment

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Novo Nordisk seeks US, EU approval for hemophilia A treatment

Novo Nordisk A/S filed a biologics license application with the US Food and Drug Administration and a marketing authorization application with the European Medicines Agency for N8-GP to treat people with hemophilia A.

Hemophilia A is caused by the genetic deficiency in clotting protein, factor VIII, resulting in increased bleeding, and usually affects males.

N8-GP is an extended half-life factor VIII, which can stay in the bloodstream for a longer duration and thus requires less frequent injections.

The submission is based on the pathfinder clinical trial program which showed that N8-GP reduced bleeding rates among adults, children as well as people undergoing surgery.